Lynne Lyons, MD
Psychiatry · West Bloomfield, MINPI 1780644880
Payments from drug & device makers
Across 626 payments — averaging $38.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$9K
- AbbVie$5K
- Janssen Scientific Affairs, LLC$2K
- Otsuka America Pharmaceutical, Inc.$2K
- Teva Pharmaceuticals USA, Inc.$1K
- Lundbeck LLC$899
- plus $5K from 22 others
What the payments were for
- Consulting fees$7,33330%
- Speaking & faculty fees$5,98025%
- Travel & lodging$9374%
- Food & beverage$9,82740%
- Education$3091%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 54 | $9,220 |
| AbbVie(2 entities) | 63 | $4,841 |
| Janssen Scientific Affairs, LLC | 1 | $1,950 |
| Otsuka America Pharmaceutical, Inc. | 120 | $1,734 |
| Teva Pharmaceuticals USA, Inc. | 53 | $1,062 |
| Lundbeck LLC | 61 | $899 |
| Takeda Pharmaceuticals U.S.A., Inc. | 31 | $737 |
| Avanir Pharmaceuticals, Inc. | 53 | $631 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 33 | $592 |
| Vanda Pharmaceuticals Inc. | 29 | $489 |
| Axsome Therapeutics, Inc. | 27 | $379 |
| Jazz Pharmaceuticals Inc. | 14 | $313 |
| Neurocrine Biosciences, Inc. | 16 | $306 |
| Alkermes, Inc. | 16 | $305 |
| Livanova USA, Inc. | 9 | $185 |
| Bausch Health US, LLC | 6 | $97 |
| Arbor Pharmaceuticals, Inc. | 5 | $81 |
| E.r. Squibb & Sons, L.L.C. | 4 | $77 |
| Neos Therapeutics, LP | 5 | $76 |
| Idorsia Pharmaceuticals US Inc | 4 | $72 |
| Ironshore Pharmaceuticals Inc. | 5 | $70 |
| Corium, LLC | 5 | $65 |
| Supernus Pharmaceuticals, Inc. | 4 | $64 |
| Shire North American Group Inc | 3 | $62 |
| Avadel CNS Pharmaceuticals, LLC | 2 | $45 |
| Lilly USA, LLC | 1 | $17 |
| Alfasigma USA, Inc. | 1 | $13 |
| Neuronetics, Inc. | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$10,529
- VRAYLAR$3,900
- REXULTI$125
- TRINTELLIX$121
How this compares
$24,386 in reported general payments places this provider in the 95th percentile of 1,166 psychiatry providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SpravatoEsketamine Hcl | 157 | $1,435,665 |
| VraylarCariprazine Hcl | 37 | $63,666 |
| NuedextaDextromethorphan Hbr/Quinidine | 20 | $33,420 |
| MounjaroTirzepatide | 26 | $30,306 |
| TrintellixVortioxetine Hydrobromide | 18 | $17,161 |
| Olanzapine OdtOlanzapine | 15 | $5,765 |
| Quetiapine Fumarate | 103 | $5,092 |
| Alprazolam ErAlprazolam | 39 | $4,517 |
| VyvanseLisdexamfetamine Dimesylate | 11 | $4,200 |
| Clozapine | 38 | $3,295 |
| Divalproex Sodium ErDivalproex Sodium | 39 | $3,032 |
| Bupropion XlBupropion Hcl | 73 | $2,494 |
| Lamotrigine | 60 | $2,191 |
| Clozapine OdtClozapine | 13 | $2,051 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 36 | $2,049 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonSpravato | $9,220 | $1,435,665157 claims |
| AbbVieVraylar | $4,841 | $63,66637 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $631 | $33,42020 claims |
| Lilly USA, LLCMounjaro, Olanzapine | $17 | $31,01660 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $737 | $21,36129 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,166 psychiatry providers in Michigan.
Other psychiatry in West Bloomfield
- Theodore RuzaWest Bloomfield$100K
- Kathleen Fouche BrazzleWest Bloomfield$12K
- Andreas SidiropoulasDetroit$2.8M
- Joel YoungRochester Hills$1.9M
- Welton WashingtonYpsilanti$1.4M
- Rajaprabhakaran RajarethinamAnn Arbor$1.2M
- Eric AchtyesGrand Rapids$705K
- Manzar RajputMonroe$612K
- William GuySouthfield$562K
- Brian MickeyAnn Arbor$490K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.